妊娠期破伤风-白喉-无细胞百日咳免疫对婴儿后续免疫血清反应的影响:一项大型随机安慰剂对照试验的随访
这项IV期多国开放标签随访研究评估了601名婴儿(母亲孕期接种Tdap组296名,对照组305名)接种DTaP-HepB-IPV/Hib和PCV13后的免疫原性与安全性。基础免疫后1个月,两组白喉、破伤风血清保护率均为100%,但孕期接种Tdap组婴儿的百日咳抗原疫苗应答率(37.5-77.1%)显著低于对照组(90.0-99.2%),不良事件发生率两组相似。
要点
- 孕期接种Tdap组婴儿百日咳抗原疫苗应答率37.5-77.1%,显著低于对照组90.0-99.2%。
- 基础免疫后1个月两组白喉、破伤风血清保护率均为100%。
- 两组不良事件发生率相似,严重不良事件Tdap组2.4%、对照组5.6%,均与接种无关。
核心结论
- 孕期转移的百日咳抗体可能降低婴儿出生后最初数月百日咳感染风险,但干扰婴儿产生百日咳抗体的能力,其临床意义仍未知。
研究设计与样本
- IV期、多国、开放标签随访研究,纳入6-14周龄婴儿,其母亲在孕期(270/7-366/7周妊娠)随机接受减抗原成分破伤风-白喉-三组分无细胞百日咳疫苗(Tdap组)或安慰剂(对照组),产后交叉免疫。
- 所有婴儿按国家免疫规划接种2或3剂DTaP-HepB-IPV/Hib和PCV13,基础免疫前和基础免疫后1个月评估免疫原性。
主要发现
- 共601名婴儿接种(Tdap组296名,对照组305名)。
- 基础免疫后1个月,两组血清保护率:白喉100%、破伤风100%、乙型肝炎≥98.5%、脊髓灰质炎≥95.9%、Hib≥94.5%。
- 百日咳抗原疫苗应答率:孕期接种Tdap组婴儿为37.5-77.1%,显著低于对照组90.0-99.2%。
- 征集性和非征集性不良事件发生率两组相似;严重不良事件Tdap组2.4%、对照组5.6%,均与接种无关。
关键数值与推荐
- 主要目标为评估基础免疫后1个月DTaP-HepB-IPV/Hib抗原的血清保护/疫苗应答率。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Pertussis immunization during pregnancy results in high pertussis antibody concentrations in young infants but may interfere with infant immune responses to post-natal immunization. METHODS: This phase IV, multi-country, open-label study assessed the immunogenicity and safety of infant primary vaccination with DTaP-HepB-IPV/Hib and 13-valent pneumococcal conjugate vaccine (PCV13). Enrolled infants (6-14 weeks old) were born to mothers who were randomized to receive reduced-antigen-content diphtheria-tetanus-three-component acellular pertussis vaccine (Tdap group) or placebo (control group) during pregnancy (270/7-366/7 weeks' gestation) with crossover immunization postpartum. All infants received 2 or 3 DTaP-HepB-IPV/Hib and PCV13 doses according to national schedules. Immunogenicity was assessed in infants pre- and 1 month post-primary vaccination. The primary objective was to assess seroprotection/vaccine response rates for DTaP-HepB-IPV/Hib antigens 1 month post-primary vaccination. RESULTS: 601 infants (Tdap group: 296; control group: 305) were vaccinated. One month post-priming, seroprotection rates were 100% (diphtheria; tetanus), ≥98.5% (hepatitis B), ≥95.9% (polio) and ≥94.5% (Hib) in both groups. Vaccine response rates for pertussis antigens were significantly lower in infants whose mothers received pregnancy Tdap (37.5-77.1%) versus placebo (90.0-99.2%). Solicited and unsolicited adverse event rates were similar between groups. Serious adverse events occurred in 2.4% (Tdap group) and 5.6% (control group) of infants, none were vaccination-related. CONCLUSIONS: Pertussis antibodies transferred during pregnancy may decrease the risk of pertussis infection in the first months of life but interfere with the infant's ability to produce pertussis antibodies, the clinical significance of which remains unknown. Safety and reactogenicity results were consistent with previous experience. CLINICAL TRIAL REGISTRATION: ClinicalTrials.gov: NCT02422264.
引用
- Perrett KP, Halperin SA, Nolan T, et al. Impact of tetanus-diphtheria-acellular pertussis immunization during pregnancy on subsequent infant immunization seroresponses: follow-up from a large randomized placebo-controlled trial. Vaccine. 2019. PMID: 31776027. doi:10.1016/j.vaccine.2019.10.104
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。